Patents by Inventor Tsukasa Ishihara

Tsukasa Ishihara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11542523
    Abstract: An object of the present invention is to provide an animal cell with improved proliferation ability and survival rate, a method for producing the animal cell, and a method for producing a target protein formed of the animal cell. According to the present invention, there is provided an animal cell having a gene encoding a target protein and a foreign gene encoding an isovaleryl-CoA dehydrogenase, in which the isovaleryl-CoA dehydrogenase is overexpressed.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 3, 2023
    Assignee: FUJIFILM Corporation
    Inventors: Tatsuya Matsuura, Tsukasa Ishihara
  • Publication number: 20220290204
    Abstract: An object of the present invention is to provide a cell culture method having an excellent cell proliferation property, an antibody production method using the above method, an organic acid removal method using the above method, and an antibody produced by the above method. The cell culture method of the present invention is a cell culture method including a metabolic decomposition product removal step of bringing a culture solution containing a metabolic decomposition product into contact with a polymer having a quaternary ammonium base group or an amino group and removing the metabolic decomposition product from the culture solution to a purified culture solution and a cell culture step of culturing cells using the purified culture solution.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 15, 2022
    Applicant: FUJIFILM Corporation
    Inventors: Katsuhiro SHIMONO, Yoshinobu HIRAI, Tsukasa ISHIHARA
  • Publication number: 20210147781
    Abstract: Provide are a cell culture method which includes using a culture vessel which contains a cell suspension containing cells and discharging a gas including 30% by volume or more of oxygen into the cell suspension from a sparger disposed in the culture vessel to culture the cells, in which an average hole diameter in a gas discharge portion in the sparger is 1 ?m or more and 300 ?m or less, and a surface area A (m2) in the gas discharge portion in the sparger, a volume X (m3) of the cell suspension in the culture vessel, and a flow rate Q (m3/min) of the gas that is discharged from the sparger satisfy a specific relationship, a product producing method including the cell culture method, and a cell culture device that enables the cell culture method.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 20, 2021
    Applicant: FUJIFILM Corporation
    Inventors: Shinichi NAKAI, Kosuke TANIGUCHI, Nobuyuki HARAGUCHI, Tsukasa ISHIHARA
  • Publication number: 20200299723
    Abstract: An object of the present invention is to provide an animal cell with improved proliferation ability and survival rate, a method for producing the animal cell, and a method for producing a target protein formed of the animal cell. According to the present invention, there is provided an animal cell having a gene encoding a target protein and a foreign gene encoding an isovaleryl-CoA dehydrogenase, in which the isovaleryl-CoA dehydrogenase is overexpressed.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 24, 2020
    Applicant: FUJIFILM Corporation
    Inventors: Tatsuya MATSUURA, Tsukasa ISHIHARA
  • Patent number: 10532048
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: January 14, 2020
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20190000832
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Application
    Filed: July 5, 2018
    Publication date: January 3, 2019
    Applicant: Selder Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 10016410
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 10, 2018
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20170189390
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Applicant: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, ltsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 9526719
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: December 27, 2016
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 9399038
    Abstract: A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: wherein R1, R2, R3, R4, R5, X and n are as described herein.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: July 26, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Tsukasa Ishihara, Kazuhiro Ikegai, Ikumi Kuriwaki, Hiroyuki Hisamichi, Nobuaki Takeshita, Ryuichi Takezawa
  • Publication number: 20150359787
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Application
    Filed: August 26, 2015
    Publication date: December 17, 2015
    Applicant: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 9150541
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: October 6, 2015
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Publication number: 20150133433
    Abstract: A method for preventing or treating a disease selected from the group consisting of visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia in a subject in need thereof, comprising administering to said subject an effective amount of the compound of the following formula (I) or a salt thereof: wherein R1, R2, R3, R4, R5, X and n are as described herein.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Tsukasa ISHIHARA, Kazuhiro IKEGAI, Ikumi KURIWAKI, Hiroyuki HISAMICHI, Nobuaki TAKESHITA, Ryuichi TAKEZAWA
  • Patent number: 8981119
    Abstract: The present invention is directed to compounds of Formula I: wherein R1, R2, R3, R4, R5, X and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are useful as IK1 channel activators.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: March 17, 2015
    Assignee: Astellas Pharma Inc.
    Inventors: Tsukasa Ishihara, Kazuhiro Ikegai, Ikumi Kuriwaki, Hiroyuki Hisamichi, Nobuaki Takeshita, Ryuichi Takezawa
  • Publication number: 20140364421
    Abstract: [Problem] A compound which is useful as an IK1 channel activator is provided. [Means for Solution] As a result of studies on the IK1 channel activator, the present inventors have found that a benzothiophene compound shows effectiveness on visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, or fibromyalgia, thereby completing the invention. A compound of the invention has an IK1 channel activation effect, and can also be used as an agent for preventing and/or treating visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, or fibromyalgia. In addition, the IK1 channel activator can be used as an agent for preventing and/or treating inflammatory pain, osteoarthritis pain, neuropathic pain, and fibromyalgia.
    Type: Application
    Filed: June 6, 2014
    Publication date: December 11, 2014
    Applicant: ASTELLAS PHARMA INC.
    Inventors: Tsukasa ISHIHARA, Kazuhiro IKEGAI, Ikumi KURIWAKI, Hiroyuki HISAMICHI, Nobuaki TAKESHITA, Ryuichi TAKEZAWA
  • Publication number: 20140058100
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Application
    Filed: July 15, 2013
    Publication date: February 27, 2014
    Applicant: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 8518490
    Abstract: In a coating zone, a cylindrical tube is soaked in and taken out from a solution, such that a coating film is formed on a curved surface of the tube. In a wet gas zone, while a first gas feeding nozzle having a gas outlet moves in a state where the gas outlet faces an outer peripheral surface of the tube, wet gas is blown toward the coating film through the gas outlet. Water drops are generated on the coating film and grown up. In a dry gas zone, as in the case of the first gas feeding nozzle, while a second gas feeding nozzle having a gas outlet moves, dry gas is blown toward the coating film through the gas outlet. Solvent and water drops are evaporated from the coating film. Pores form from the water drops as a template for the porous material on the coating film.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: August 27, 2013
    Assignee: Fujifilm Corporation
    Inventors: Koju Ito, Tsukasa Ishihara, Hidekazu Yamazaki
  • Patent number: 8486970
    Abstract: [Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). [Means for Solving Problems] It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: May 26, 2008
    Date of Patent: July 16, 2013
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Patent number: 8187852
    Abstract: A porous film is used as a cell culture substrate that is a scaffold for a spheroid. The porous film has a plurality of pores whose diameters gradually increase in a direction A. The diameters of the pores gradually increase from a first area P1 to a third area P3 in this order. The first to the third areas P1 to P3 are located on the porous film along the direction A. The diameters and depths of the pores increase in proportion to the distance in the direction A.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: May 29, 2012
    Assignee: FUJIFILM Corporation
    Inventors: Hidekazu Yamazaki, Tsukasa Ishihara
  • Patent number: RE43481
    Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4?-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: June 19, 2012
    Assignee: Astellas Pharma Inc.
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe